Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022
Hepatocellular carcinoma (HCC) is a malignant digestive tract tumor with extremely high morbidity and mortality. In recent years, diagnosis and treatment of HCC have made significant improvements in China. New technologies such as single-cell sequencing, spatial-omics sequencing and deep learning-ba...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-04-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1684137954134-1149358805.pdf |
| _version_ | 1797822445537722368 |
|---|---|
| author | ZHAO Haichao, GAO Qiang |
| author_facet | ZHAO Haichao, GAO Qiang |
| author_sort | ZHAO Haichao, GAO Qiang |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a malignant digestive tract tumor with extremely high morbidity and mortality. In recent years, diagnosis and treatment of HCC have made significant improvements in China. New technologies such as single-cell sequencing, spatial-omics sequencing and deep learning-based artificial intelligence have led to breakthroughs in basic research of liver cancer. A more comprehensive understanding of the biological characteristics of HCC will push the breakthroughs in industry-university-research and clinical treatment and become the key to improving the treatment efficacy of HCC. With the publication of the results of several large-scale prospective clinical studies such as FOLFOX-HAIC, LEAP-002 and KEYNOTE-301, more possibilities for postoperative HCC and HCC patients with failure of first-line treatment have been opened up. Pushing the boundaries of local and systemic treatment options, new translational studies (TALENTop and IBI305) have further transformed intermediate to advanced hepatocellular carcinoma into surgically resectable disease, giving more patients with HCC the opportunity to be saved. This article summarized the basic and clinical research progress in the field of HCC in 2022. |
| first_indexed | 2024-03-13T10:09:09Z |
| format | Article |
| id | doaj.art-06a70ee10cb748bf8dbf7baa62d9028e |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-03-13T10:09:09Z |
| publishDate | 2023-04-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-06a70ee10cb748bf8dbf7baa62d9028e2023-05-22T06:52:10ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392023-04-0133431532610.19401/j.cnki.1007-3639.2023.04.002Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022ZHAO Haichao, GAO Qiang0Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaHepatocellular carcinoma (HCC) is a malignant digestive tract tumor with extremely high morbidity and mortality. In recent years, diagnosis and treatment of HCC have made significant improvements in China. New technologies such as single-cell sequencing, spatial-omics sequencing and deep learning-based artificial intelligence have led to breakthroughs in basic research of liver cancer. A more comprehensive understanding of the biological characteristics of HCC will push the breakthroughs in industry-university-research and clinical treatment and become the key to improving the treatment efficacy of HCC. With the publication of the results of several large-scale prospective clinical studies such as FOLFOX-HAIC, LEAP-002 and KEYNOTE-301, more possibilities for postoperative HCC and HCC patients with failure of first-line treatment have been opened up. Pushing the boundaries of local and systemic treatment options, new translational studies (TALENTop and IBI305) have further transformed intermediate to advanced hepatocellular carcinoma into surgically resectable disease, giving more patients with HCC the opportunity to be saved. This article summarized the basic and clinical research progress in the field of HCC in 2022.http://www.china-oncology.com/fileup/1007-3639/PDF/1684137954134-1149358805.pdf|hepatocellular carcinoma|cancer screening|basic research|clinical research |
| spellingShingle | ZHAO Haichao, GAO Qiang Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 Zhongguo aizheng zazhi |hepatocellular carcinoma|cancer screening|basic research|clinical research |
| title | Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 |
| title_full | Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 |
| title_fullStr | Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 |
| title_full_unstemmed | Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 |
| title_short | Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 |
| title_sort | progress in research diagnosis and treatment of hepatocellular carcinoma in 2022 |
| topic | |hepatocellular carcinoma|cancer screening|basic research|clinical research |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1684137954134-1149358805.pdf |
| work_keys_str_mv | AT zhaohaichaogaoqiang progressinresearchdiagnosisandtreatmentofhepatocellularcarcinomain2022 |